Navigation Links
Quantitative PET imaging finds early determination of effectiveness of cancer treatment

RESTON, Va.With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patients response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors. Researchers have found that measuring a quantitative indexone that reflects the reduction of metabolic activity after chemotherapy first beginsadds accurate information about patients responses to first-line chemotherapy, according to a study in the October issue of the Journal of Nuclear Medicine.

In our study, we demonstrated that a quantitative assessment of therapeutic response for patients with diffuse large B-cell lymphoma (DLBCL) is more accurate than visual analysis alone when using the radiotracer FDG (fluorodeoxyglucose) with PET scans, said Michel Meignan, professor of nuclear medicine at Henri Mondor Hospital in Creteil, France. The ability to predict tumor response early in the course of treatment is very valuable clinically, allowing intensification of treatment in those patients who are unlikely to response to first-line chemotherapy, he added. Similarly, treatment could possibly be shortened in those patients who show a favorable response after one or two cycles of chemotherapy, and quantification also may help identify the diseases transformation from low-grade to aggressive stage, he explained. However, visual interpretation of PET scans will always be the first step of analysis and will prevail in case of difficulties to quantify images, added Meignan.

Diffuse large B-cell lymphoma is a fast-growing, aggressive form of non-Hodgkin lymphoma, a cancer of the bodys lymphatic system. Although there are more than 20 types of NHL, DLBCL is the most common type, making up about 30 percent of all lymphomas. In the United States, about 63,190 people are expected to be diagnosed with non-Hodgkin lymphoma in 2007, according to recent statistics.

Ninety-two patients with DLBCL were studied before and after two cycles of chemotherapy, and tumor response was assessed visually and by various quantitative parameters, explained the co-author of Early 18F-FDG PET for Prediction of Prognosis in Patients With Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis. Meignan said, We found that quantification of tumor FDG uptake (the ratio of tissue radioactivity concentration) can markedly improve the accuracy of FDG PET for prediction of patient outcome. Additional studies need to be done, said Meignan, reiterating that the future monitoring of cancer tumor response will probably include a combination of quantitative analysis and visual assessment.

PET is a powerful molecular imaging procedure that uses very small amounts of radioactive materials that are targeted to specific organs, bones or tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET scanning provides information about the bodys chemistry, metabolic activity and body function.


Contact: Maryann Verrillo
Society of Nuclear Medicine

Related biology news :

1. Imaging Lymph Nodes with Nanoparticles
2. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
3. Special Imaging Study Shows Failing Hearts Are Energy Starved
4. Duke engineers develop new 3-D cardiac imaging probe
5. Confocal imaging promises early detection of skin cancer
6. Newer imaging techniques may lead to over-treatment
7. Researchers use 3-D imaging system to unveil swimming behavior of microscopic plankton
8. Microscopic brain imaging in the palm of your hand
9. New imaging technology shown to detect pancreatic inflammation in type 1 diabetes
10. Purdues gold nanorods brighten future for medical imaging
11. PET imaging reveals the immune system at work
Post Your Comments:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: